KlineMPRajkumarSVTimmMM, et al. ABT-737, an inhibitor of BCL-2 family proteins, is a potent inducer of apoptosis in multiple myeloma cells. Leukemia. 2007;21(7):1549-1560. doi:10.1038/sj.leu.2404719.
2.
BodetLGomez-BougiePTouzeauC, et al. ABT-737 is highly effective against molecular subgroups of multiple myeloma. Blood. 2011;118:3901-3910. doi:10.1182/blood-2010-11-317438.
3.
TouzeauCDoussetCLe GouillS, et al. The BCL-2 specific BH3 mimetic ABT-199: a promising targeted therapy for t(11;14) multiple myeloma. Leukemia. 2014;28(1):210-212. doi:10.1038/leu.2013.216.
4.
KumarSKHarrisonSJCavoM, et al. Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial. Lancet Oncol. 2020;21(12):1630-1642. doi:10.1016/S1470-2045(20)30525-8.
CairoMSBishopM.Tumour lysis syndrome: new therapeutic strategies and classification. Br J Haematol. 2004;127(1):3-11. doi:10.1111/j.1365-2141.2004.05094.x.
7.
BrasierARNussbaumSR.Hungry bone syndrome: clinical and biochemical predictors of its occurrence after parathyroid surgery. Am J Med. 1988;84(4):654-660. doi:10.1016/0002-9343(88)90100-3.
8.
BlomqvistCP.A hospital survey of hypocalcemia in patients with malignant disease. Acta Med Scand. 1986;220(2):167-173. doi:10.1111/j.0954-6820.1986.tb02745.x.
9.
NaranjoCABustoUSellersEM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30(2):239-245. doi:10.1038/clpt.1981.154.
